Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glomerular Filtration Rate Clear all
Completed Phase 2 Interventional Results available

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

NCT04724837
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan, Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
50
States / cities
Huntsville, Alabama • Beverly Hills, California • Downey, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Estimating Glomerular Filtration Rate in Kidney Transplant Recipients

NCT05229939
View directory record Official record
Conditions
Kidney Transplantation, Glomerular Filtration Rate
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
11,412 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

NCT03810833
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Brilliance device sensor
Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers

NCT02098187
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180, 4 times above target dose MP-3180, ORFM prototype, Iohexol comparator
Drug · Device · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Phase 3 Interventional

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

NCT06217302
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

NCT00750620
View directory record Official record
Conditions
Renal Impairment
Interventions
YM178
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

NCT03605810
View directory record Official record
Conditions
Renal Function
Interventions
No Intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,132,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS

NCT02276066
View directory record Official record
Conditions
Sepsis
Interventions
GFR by Iohexol, Urine Collection, Blood samples
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Metformin Therapy in ADPKD

NCT02903511
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Delaying the Progression of Diabetic Nephropathy in Pima Indians

NCT00353600
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 10, 2026, 2:27 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Determination of Kidney Function

NCT00001978
View directory record Official record
Conditions
Kidney Disease, Proteinuria, Autoimmune / Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Withdrawn Phase 3 Interventional

Empaglifozin in Early Diabetic Kidney Disease

NCT03173963
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

NCT01319591
View directory record Official record
Conditions
CNS Lymphoma, CNS Involvement of Systemic Lymphoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance

NCT01545531
View directory record Official record
Conditions
Renal Disease, Renal Insufficiency
Interventions
Iohexol
Drug
Lead sponsor
University of Washington
Other
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

NCT02521181
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate, Placebo
Drug
Lead sponsor
Jennifer Gassman, PhD
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

NCT00830037
View directory record Official record
Conditions
Chronic Kidney Disease, Iron-deficiency Anemia
Interventions
IV Iron, Ferrous Sulfate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Not applicable Interventional

A New Combination of Evidence-Based Interventions to Improve Primary Care Diagnostic Safety and Efficiency

NCT05735314
View directory record Official record
Conditions
Anemia, Decreased Glomerular Filtration Rate
Interventions
Enhanced diagnostic team implementing three evidence-based interventions, Usual care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

NCT00461006
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Actos, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Peoria, Arizona • Jonesboro, Arkansas • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glomerular Injury of Preeclampsia

NCT00275158
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
L-Arginine Supplementation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655
View directory record Official record
Conditions
Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
Interventions
Not listed
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases

NCT02639260
View directory record Official record
Conditions
Kidney Disease
Interventions
N-acetyl D-mannosamine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jun 10, 2026, 2:27 PM EDT